Group 1 - The core viewpoint of the article highlights the significant stock price increase of Haixi Pharmaceutical, which rose over 7% and is currently trading at 140.9 HKD, with a market capitalization exceeding 11 billion HKD [1] - Haixi Pharmaceutical is a commercial-stage pharmaceutical company that integrates research, production, and sales capabilities, with a pipeline of innovative drugs under development [1] - As of the date of the prospectus disclosure, Haixi Pharmaceutical has received approval for 15 generic drug products, covering various therapeutic areas including the digestive system, cardiovascular system, endocrine system, and nervous system [1] Group 2 - The company has established a pipeline of four innovative drugs currently under development, targeting diseases in oncology, ophthalmology, and respiratory systems [1] - The average daily market capitalization of Haixi Pharmaceutical has reached 99.4 billion HKD, which is above the threshold required for Hong Kong Stock Connect [1]
海西新药一度涨超7% 总市值现突破110亿港元